Supported in part by a grant from Eli Lilly.‡
Paul Keck Jr, MD, is employed by the University of Cincinnati College of Medicine, University of Cincinnati Physicians, and the Lindner Center of HOPE; Dr. Keck is presently or has been in the past year a principal or co-investigator on research studies sponsored by Alkermes, AstraZeneca, Cephalon, GlaxoSmithKline, Eli Lilly and Company, Epi-Q, Jazz Pharmaceuticals, Marriott Foundation, National Institute of Mental Health (NIMH), Orexigen, Pfizer, Shire; Dr. Keck has been reimbursed for consulting to, in the past year: 2010: Sepracor, Medco, 2009: BristolMyersSquibb, GlaxoSmithKline, Pfizer, QuantiaMD, Schering Plough, Patents: Dr. Paul E. Keck Jr. is a co-inventor on United States Patent No. 6,387,956: Shapira NA, Goldsmith TD, Keck, PE Jr. (University of Cincinnati) Methods of treating obsessive-compulsive spectrum disorder comprises the step of administering an effective amount of tramadol to an individual. Filed March 25, 1999; approved May 14, 2002; Dr. Keck has received no financial gain from this patent. Susan L. McElroy, MD, is employed by the University of Cincinnati College of Medicine, University of Cincinnati Physicians, and the Lindner Center of HOPE; Dr. McElroy is a consultant to, or member of the scientific advisory boards of Alkermes, Eli Lilly and Company, Shire; Dr. McElroy is a principal or co-investigator on research studies sponsored by Agency for Healthcare Research & Quality (AHRQ), Alkermes, AstraZeneca, Bristol-Myers Squibb, Cephalon, Eli Lilly and Company, Forest Labs, GalaxoSmith Kline, Jazz Pharmaceuticals, Marriott Foundation, National Institute of Mental Health, Orexigen Therapeutics, Pfizer Shire, Takeda Pharmaceutical Company Limited; Patents: Dr. Susan L. McElroy is also inventor on United States Patent No. 6,323,236 B2, Use of Sulfamate Derivatives for Treating Impulse Control Disorders, and, along with the patent's assignee, University of Cincinnati, Cincinnati, OH, has received payments from Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has exclusive rights under the patent. James I. Hudson, MD, has been a consultant for Eli Lilly, Pfizer, and Alkermes; and has received grant support from Eli Lilly, Otsuka, and Ortho-McNeil Janssen Scientific Affairs. Erik B. Nelson, MD, has received funding for clinical trials with Astra Zeneca, Novartis and Pamlab. Drs. Erin L. Winstanley and Anna I. Guerdjikova and Mrs. Nicole Mori and Jessica McCoy have no industry/commercial support or conflicts of interest to disclose.